Aegerion Pharmaceuticals, Inc. (Nasdaq: AEGR) announced the primary endpoint was achieved in the Company's open-label, multicenter study to evaluate the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE